ACME UNITED CORP - 10-Q Summary (Q1 1998)
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ACME UNITED CORP for the period ended March 31, 1998. The company operates in consumer and medical product sectors, with significant foreign operations. As of April 30, 1998, there were 3,369,875 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Sales | $11,045,000 | $10,880,000 |
| Gross Profit Margin | 29.4% | 32.6% |
| Net (Loss) Income | $(92,000) | $281,000 |
| Diluted EPS | $(0.03) | $0.08 |
| Net Cash Used by Operating Activities | $(198,000) | $(118,000) |
| Total Debt (Current + Long Term) | $16,316,000 | N/A (Prior period not explicitly totaled) |
| Working Capital | $10,573,000 | N/A |
| Current Ratio | 1.90 | N/A |
Material Changes vs. Prior Period
- Revenue: Net sales increased 2% year-over-year. On an adjusted basis (accounting for the sale of the Seton product line in 1997 and the acquisition of Rotex in late 1997), sales increased 7%.
- Profitability: The company reported a net loss of $92,000 compared to a net income of $281,000 in the prior year. This reversal was driven by a decline in gross margins and the absence of a one-time gain on the sale of marketing rights to Seton in 1997.
- Margins: Gross profit margin declined from 32.6% to 29.4%. The medical business margin dropped significantly from 39.9% to 34.3% due to sales mix changes and the loss of the Seton line.
- Expenses: SG&A expenses decreased 11% to $2,635,000, aided by headcount reductions in the UK and the elimination of expenses related to sold product lines.
- Debt: Total debt increased by $737,000 during the quarter to support capital expenditures and sales growth.
Outlook, Risks, and Management Commentary
- Liquidity: Management expects cash generated from operations for the remainder of 1998 to be sufficient to reduce debt and fund capital expenditures. Current debt and credit arrangements are deemed adequate for liquidity needs.
- Seasonality: Sales are traditionally weaker in the first and fourth quarters.
- Legal and Environmental: The company is involved in environmental matters and legal actions regarding latex products it distributes (but does not manufacture). Management does not expect a significant financial impact.
- Year 2000 Compliance: A new information system was implemented in 1997 to address Y2K issues. A task force is evaluating remaining impacts, and management believes the issue will not materially affect future financial results.
Investor Verification Checklist
- Verify the sustainability of the 7% adjusted sales growth given the decline in the medical product segment.
- Monitor the trend in gross profit margins, specifically the compression in the medical business.
- Assess the company's ability to generate positive operating cash flow to service the increased debt load.
- Review the status of ongoing legal proceedings regarding latex products for potential contingent liabilities.
- Confirm the progress of the Year 2000 compliance assessment and any associated costs.